

ORIGINAL ARTICLE

Epigenetic silencing of miR-124 prevents spermine oxidase regulation: implications for *Helicobacter pylori*-induced gastric cancerT Murray-Stewart¹, JC Sierra², MB Piazuelo², RM Mera², R Chaturvedi^{2,3}, LE Bravo⁴, P Correa², BG Schneider², KT Wilson^{2,5} and RA Casero¹

Chronic inflammation contributes to the development of various forms of cancer. The polyamine catabolic enzyme spermine oxidase (SMOX) is induced in chronic inflammatory conditions, including *Helicobacter pylori*-associated gastritis, where its production of hydrogen peroxide contributes to DNA damage and subsequent tumorigenesis. MicroRNA expression levels are also altered in inflammatory conditions; specifically, the tumor suppressor miR-124 becomes silenced by DNA methylation. We sought to determine if this repression of miR-124 is associated with elevated SMOX activity and concluded that miR-124 is indeed a negative regulator of SMOX. In gastric adenocarcinoma cells harboring highly methylated and silenced *mir-124* gene loci, 5-azacytidine treatment allowed miR-124 re-expression and decreased SMOX expression. Overexpression of an exogenous miR-124-3p mimic repressed SMOX mRNA and protein expression as well as H₂O₂ production by >50% within 24 h. Reporter assays indicated that direct interaction of miR-124 with the 3'-untranslated region of SMOX mRNA contributes to this negative regulation. Importantly, overexpression of miR-124 before infection with *H. pylori* prevented the induction of SMOX believed to contribute to inflammation-associated tumorigenesis. Compelling human *in vivo* data from *H. pylori*-positive gastritis tissues indicated that the *mir-124* gene loci are more heavily methylated in a Colombian population characterized by elevated SMOX expression and a high risk for gastric cancer. Furthermore, the degree of *mir-124* methylation significantly correlated with SMOX expression throughout the population. These results indicate a protective role for miR-124 through the inhibition of SMOX-mediated DNA damage in the etiology of *H. pylori*-associated gastric cancer.

Oncogene (2016) 35, 5480–5488; doi:10.1038/onc.2016.91; published online 4 April 2016

INTRODUCTION

Spermine oxidase (SMOX), an inducible enzyme in the polyamine catabolic pathway, is responsible for the direct back-conversion of spermine to spermidine.¹ This FAD (flavin adenine dinucleotide)-dependent reaction also generates significant amounts of the reactive oxygen species (ROS) precursor hydrogen peroxide (H₂O₂) as a byproduct. SMOX activity occurs in the cytoplasm as well as the nucleus,^{2,3} where its production of H₂O₂ in close proximity to DNA results in oxidative DNA damage that elevates the potential for neoplastic transformation. To further exacerbate this potential, spermine, the substrate of SMOX, functions as a free-radical scavenger⁴ and is diminished during SMOX-mediated ROS generation. SMOX is induced in response to various stimuli, including bacterial infection,^{5–7} proinflammatory cytokines,⁸ the natural polyamines and certain polyamine analogs.¹ Importantly, significant increases in SMOX protein expression have been detected in tissues from patients harboring conditions characterized by chronic inflammation, including *Helicobacter pylori*-associated gastritis,⁹ prostatic intraepithelial neoplasia (PIN)¹⁰ and ulcerative colitis.¹¹ Each of these conditions increases the risk of tumorigenesis, and the inhibition or loss of SMOX activity in animal models representing these conditions decreases tumor occurrence.^{7,12,13} Elevated SMOX thereby serves as a molecular

link between infection and/or inflammatory stimuli and the development of chronic inflammation-associated tumorigenesis.

Much research has focused on *H. pylori*-mediated induction of SMOX in gastric epithelial cells as a mechanism linking chronic gastritis and gastric carcinogenesis. A Gram-negative, microaerophilic bacterium, *H. pylori* inhabits the gastric mucosae of greater than half of the world's population, and chronic infection with *H. pylori* is causally linked to gastritis and peptic ulcer disease.¹⁴ Furthermore, *H. pylori* infection is considered the predominant risk factor for the development of gastric cancer, with ~90% of newly diagnosed noncardia gastric cancer cases attributable to chronic *H. pylori* infection.¹⁵ With a 5-year survival rate of <15%, gastric cancer is the third leading cause of cancer-related deaths worldwide.^{16–18}

The prevalence of *H. pylori* infection is greatest in developing countries, and throughout the Department of Nariño, Colombia, ~80% of children are *H. pylori*-positive by the age of 5 years.¹⁹ However, the risk of eventually developing gastric cancer differs greatly between residents of two geographically isolated regions: those inhabiting the rural Andes mountain villages have an ~25-fold greater risk of developing gastric cancer than those residing in the low-risk region along the Pacific coast.²⁰ Importantly, gastric tissues biopsied from gastritis patients in the high-risk region

¹Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; ²Vanderbilt University Medical Center, Division of Gastroenterology, Nashville, TN, USA; ³Jawaharlal Nehru University School of Biotechnology, New Delhi, India; ⁴Department of Pathology, Universidad del Valle School of Medicine, Cali, Colombia and ⁵Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, USA. Correspondence: Dr RA Casero, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Bunting ◊ Blaustein Building, Room 551, 1650 Orleans Street, Baltimore, MD 21287, USA. E-mail: rcasero@jhmi.edu

Received 28 July 2015; revised 29 December 2015; accepted 4 January 2016; published online 4 April 2016

demonstrate elevated SMOX activity that results in increased oxidative DNA damage, relative to similarly staged patients from the low-risk region.¹³ These results, combined with related studies in a Mongolian gerbil model,¹³ implicate SMOX as the mediator of increased *H. pylori*-associated gastric cancer risk in the Andean population and suggest the use of aberrant SMOX induction as an indicator of gastric cancer risk and a rational target for chemoprevention.

The dysregulation of specific microRNAs (miRNAs) with tumor-suppressive or oncogenic roles is prevalent in cancer. miRNAs are short, ~22-nt-long, non-coding RNA molecules that negatively regulate target mRNA transcripts, typically through base pairing with a region in the 3'-untranslated region (3'-UTR). As tumor suppressor genes, mature miRNAs bind to the mRNA transcripts of genes with potentially oncogenic functions, downregulating their expression via message destabilization or translational inhibition. Tumor-suppressive miRNAs are frequently inactivated in cancer through multiple mechanisms, including epigenetic changes such as aberrant promoter-region DNA hypermethylation. Of interest, human miR-124 is encoded by three loci: *mir-124-1* (8p23.1), *mir-124-2* (8q12.3) and *mir-124-3* (20q13.33). Each of these is associated with a canonical CpG island that becomes densely hypermethylated, resulting in tumor-specific epigenetic repression that has been observed in many cancer types, including gastric, colon and prostate.^{21–24}

A chronic inflammatory microenvironment contributes to epigenetic silencing through DNA hypermethylation, which accumulates in non-cancerous gastric mucosae before the development of malignancy.²⁵ Several studies have implicated correlations between miR-124 epigenetic inactivation and a

predisposition to tumorigenesis. In particular, *mir-124* hypermethylation has been reported in several premalignant conditions that are associated with chronic inflammation and/or infection, and *mir-124* hypermethylation is frequently observed in gastric biopsies of individuals with *H. pylori* infection.²¹ However, the relationship of *mir-124* methylation to the mechanism of gastric carcinogenesis has not been determined. Similarly, *mir-124* DNA hypermethylation was detected in colonic tissues of both pediatric and adult patients with active ulcerative colitis,^{22,26} a colorectal cancer predisposition, as well as in premalignant cervical lesions.²⁷

The above-mentioned infection/inflammation-associated conditions under which *mir-124* becomes silenced through DNA hypermethylation mimic those in which SMOX becomes activated. Therefore, we hypothesized that miR-124 is a negative regulator of SMOX that prevents the DNA-damaging and tumorigenic effects of SMOX induction. We directly tested this hypothesis and herein present both *in vitro* and *in vivo* human data implicating the epigenetic inactivation of *mir-124* during *H. pylori*-associated gastritis as a key player in the induction of SMOX-mediated oxidative DNA damage and potential for gastric carcinogenesis.

RESULTS

Exogenous expression of miR-124 decreases SMOX expression

AGS human gastric adenocarcinoma cells express nearly undetectable levels of mature miR-124,²¹ and we have previously demonstrated that AGS cells induce SMOX expression in response to *H. pylori* infection.^{6,13} To determine if increasing miR-124 expression in these cells would alter the expression of SMOX, transient transfections were conducted using a miRNA mimic




Figure 1. Exogenous expression of miR-124 decreases SMOX expression in gastric adenocarcinoma cells. AGS cells were transfected with the miR-124-3p or negative control mimic (miR-NC) for 24 h and analyzed for the following: **(a)** RT-PCR of miR-124 expression with U6 snRNA amplification as a normalization control. **(b)** qRT-PCR of key polyamine pathway enzymes, normalized to *GAPDH*. Data are presented as the relative expression level in cells containing miR-124 versus miR-NC. (SAT1, spermidine/spermine *N*¹-acetyltransferase; ODC1, ornithine decarboxylase; AMD1, *S*-adenosylmethionine decarboxylase; SRM, spermidine synthase; SMS, spermine synthase). **(c)** Western blot using antibodies to SMOX and β -actin. **(d)** SMOX activity assays measured as pmol H_2O_2 produced per mg protein per min. **(e)** Intracellular polyamine pool concentrations (SPM, spermine; SPD, spermidine; PUT, putrescine). Histograms in **(b)**, **(d)** and **(e)** represent the means of four independent experiments, with error bars indicating s.e.m. Student's *t*-test was used to calculate two-tailed *P*-values (***P* < 0.01; **P* < 0.05).

corresponding to hsa-miR-124-3p: after 24 h, miR-124 was highly expressed, while *SMOX* mRNA expression was significantly down-regulated (>50%), compared with cells transfected with a negative control miRNA mimic (miR-NC) (Figures 1a and b). *SMOX* protein levels were also diminished upon miR-124 expression, as indicated by western blot analyses (Figure 1c). Both the decreased generation of H_2O_2 specifically from the oxidation of spermine (Figure 1d) and the increased level of spermine (Figure 1e), the substrate of *SMOX* and a free-radical scavenger,^{4,28} verified the reduction in enzymatically active *SMOX* following expression of miR-124. Intracellular concentrations of the other natural polyamines were not significantly affected, as the inhibition of *SMOX* does not elicit a complete blockade of polyamine metabolism. Of the other polyamine metabolic enzymes, *S-adenosylmethionine decarboxylase* (*AMD1*) and *spermidine synthase* (*SRM*) mRNA expression levels were also decreased following miR-124 transfection (Figure 1b). As neither of these transcripts is predicted to bind miR-124, it is likely that this downregulation of biosynthesis is due to feedback from the observed increase in intracellular spermine concentration.²⁹

miR-124 directly targets the 3'-UTR of *SMOX*

To determine if *SMOX* is a direct target of miR-124, the 3'-UTR of the human *SMOX* gene was examined for predicted miRNA recognition sites. Bioinformatic analysis revealed a miR-124 target site starting at position 262 of the human *SMOX* 3'-UTR that consists of an exact match to positions 2–8 of the mature miRNA (the seed+position 8) (Figure 2a). This region of the human *SMOX* gene, which is broadly conserved among vertebrates, was isolated and inserted downstream of the firefly luciferase gene to generate a reporter construct. Transfection of the resulting plasmid into AGS cells induced robust luciferase activity that was attenuated ~60% upon co-transfection with the miR-124 mimic (Figure 2b). miR-124 was unable to significantly decrease luciferase activity when co-transfected with mutated versions of the same region. Furthermore, AGS cells stably overexpressing the *SMOX* coding region but lacking the predicted miR-124 binding site continued to express elevated *SMOX* mRNA following miR-124 mimic transfection (Figure 2c). These results indicate that miR-124 regulates *SMOX*, at least in part, through direct targeting of its 3'-UTR.

miR-124 inhibits *H. pylori*-mediated induction of *SMOX*

Infection of gastric epithelial cells with *H. pylori* induces *SMOX* expression that results in increased DNA damage in association with gastric tumorigenesis.^{6,9,12,13,30} To determine if the expression of miR-124 could influence *H. pylori*-mediated *SMOX* induction, AGS gastric epithelial cells were transfected with miR-124 or the negative control mimic 48 h before infection with *H. pylori*. Quantitative PCR results demonstrated significant (6–8-fold) increases in *SMOX* mRNA in wild-type AGS cells or those containing the negative control miRNA mimic following coin-cubation with *H. pylori*, whereas the cells transfected with the miR-124 mimic maintained *SMOX* mRNA levels that were not significantly greater than basal levels (Figure 3a). These results indicate that miR-124 is capable of negatively regulating the increased *SMOX* transcript levels that occur with *H. pylori* infection, thereby potentially preventing the *SMOX*-mediated production of DNA-damaging H_2O_2 .

To confirm this protective role for miR-124, *SMOX* activity and the resultant generation of H_2O_2 were analyzed following the exposure of miR-124-expressing AGS cells to *H. pylori* (Figure 3b). As with *SMOX* mRNA, significantly increased *SMOX* activity occurred following 6 h of incubation with *H. pylori* in either wild-type or negative control AGS cells. Importantly, the AGS cells overexpressing miR-124 generated diminished levels of spermine oxidation-specific H_2O_2 , regardless of the presence of *H. pylori*.




Figure 2. miR-124 directly targets the *SMOX* 3'-UTR. **(a)** Complementarity of the 3'-UTR of wild-type (WT) or mutant (mut) human *SMOX* mRNA (starting at nucleotide +262) with the hsa-miR-124 seed sequence (red text). **(b)** Luciferase assay indicating miR-124 mimic expression attenuates reporter plasmid activity through direct interaction with the WT *SMOX* 3'-UTR. Luciferase activity was measured in RLUs and normalized to β -galactosidase activity (n=2 measured in triplicate; error bars = s.e.m.; **P < 0.05). **(c)** AGS cells transfected with the *SMOX* coding region lacking the 3'-UTR (*SMOX* OX) or empty vector (V). qRT-PCR data depict *SMOX* expression levels after transfection with miR-124 or miR-NC mimics, relative to *GAPDH*. Columns represent the means (n=2) with s.e.m.

These data verify that miR-124 is a negative regulator of *SMOX* and as such serves to protect cells from the DNA-damaging effects known to result from increased spermine oxidation in association with *H. pylori* infection.

Re-expression of endogenous miR-124 correlates with decreased *SMOX*

Previous studies have demonstrated that simultaneous CpG-island DNA hypermethylation of the promoter regions of the three *mir-124* genes is responsible for its lack of expression in AGS cells.²¹ We therefore treated AGS cells with the DNA methyltransferase inhibitor 5-azacytidine (5-azaC) to induce re-expression of endogenous miR-124 and observe its effects on *SMOX* expression. Treatment with 5-azaC resulted in a dose-dependent increase in miR-124 expression (Figure 4a) that correlated with decreased expression of the *SMOX* transcript (Figure 4b). This negative correlation was confirmed by regression analysis of the individual expression levels at each 5-azaC concentration, with *r* and *P*-values calculated using Spearman's rank correlation (Figure 4c).




Figure 3. Overexpression of miR-124 inhibits *H. pylori*-mediated induction of SMOX. AGS cells expressing the miR-NC or miR-124 mimics were exposed to *H. pylori* for 6 h. (a) qRT-PCR demonstrates that miR-124 expression represses the increase in *SMOX* mRNA typically observed in response to *H. pylori* infection. (b) SMOX activity assay demonstrating a lack of *H. pylori*-mediated spermine oxidation (measured as pmol H_2O_2 produced per mg protein per min and presented as fold-change) in the presence of miR-124. Columns represent the means ($n \geq 3$; error bars = s.e.m.).




Figure 4. Re-expression of endogenous miR-124 correlates with repressed *SMOX* expression. AGS cells were treated with 5-azacytidine (5-azaC) every 48 h (three treatments total). RNA expression levels were quantified using qRT-PCR with primers specific to miR-124 (a) or *SMOX* (b). miR-124 transcript levels are relative to U6, and *SMOX* levels are relative to *GAPDH*. Columns indicate the means ($n = 3$), with error bars indicating s.e.m. In (c), expression levels from the individual experiments in (a) and (b) were used for regression analysis. Spearman's rank correlation was used to calculate r and P -values. SMOX activity (d) following 5-azaC treatment was measured as pmol H_2O_2 /mg protein per min ($n = 3$ independent experiments measured in triplicate; error bars = s.e.m.; * $P < 0.01$; *** $P < 0.001$).

Consequently, the production of SMOX-specific hydrogen peroxide was decreased with increasing concentrations of 5-azaC (Figure 4d), suggesting that re-expression of endogenous miR-124 was capable of downregulating SMOX. Among the other genes in the polyamine pathway, only *ODC1* expression was significantly altered by 5-azaC (Supplementary Figure 1).

miR-124 DNA methylation in gastric biopsies from at-risk Colombian gastritis populations

To investigate the clinical implications of the miR-124–SMOX interaction, methylation levels of the three *hsa-mir-124* genes were quantitatively analyzed using Pyrosequencing of gastric mucosae DNA obtained from 90 patients with dyspeptic symptoms who resided in the high- or low-risk regions of Nariño, Colombia. We previously demonstrated that these same high-risk patients maintain significantly elevated levels of DNA-damaging SMOX activity that correlates with their increased risk of developing gastric cancer, relative to the low-risk patients.¹³ The majority of patients (90%) was *H. pylori*-positive and included 43 persons from the low-risk coastal region and 47 persons from the high-risk Andean region. The overall DNA methylation levels of *mir-124* were significantly elevated in the high-risk population compared with those of the low-risk group at each of the three gene loci (Figure 5). Notably, the methylation level at each genomic locus in an individual patient was positively correlated with those at the other two loci in the same patient (*mir-124-1* vs *mir-124-2*: $r = 0.679$, $P < 0.0001$; *mir-124-1* vs *mir-124-3*: $r = 0.618$, $P < 0.0001$; *mir-124-2* vs *mir-124-3*: $r = 0.742$, $P < 0.0001$), strengthening the potential for epigenetic silencing of *mir-124* in the patient as well as in the Andean population as a whole. These observations are consistent with *mir-124* epigenetic downregulation as a mechanism that allows for the chronically elevated SMOX activity and oxidative DNA damage that contributes to the high tumorigenic risk of the Andean community.¹³

It is important to note that although the coastal Colombian population has been historically referred to as ‘low-risk’ relative to the Andean population, inhabitants of the coastal region remain at significant risk for developing gastric cancer. Considering this risk and the fact that patients in both regions have advanced lesions, we applied multivariate analyses using the entire Colombian cohort




Figure 5. Methylation levels of *mir-124* genes are elevated in gastritis patient biopsies from the high-risk region versus the low-risk region. The CpG methylation percentage at each *mir-124* gene locus was determined using pyrosequencing of bisulfite-modified DNA from patients residing in the low-risk (LR) coastal region ($n = 43$) or the high-risk (HR) ($n = 47$) mountain region (assays were performed using coded case numbers). The mean methylation percentages of each patient population are presented as dots, with error bars indicating 95% confidence interval. Statistically significant differences between the two populations ($P < 0.05$) are as indicated.

to estimate the overall relationship between methylation levels of the *mir-124* gene loci and expression of SMOX, which was previously determined by immunohistochemistry.¹³ After adjusting for confounding variables, including *H. pylori* infection status and *cagA* status, age, histopathology score and risk region, generalized linear models indicated that SMOX expression was significantly and positively associated with the degree of DNA methylation at each of the three *mir-124* gene loci (Figures 6a–d). These compelling human *in vivo* data imply that increased methylation of *mir-124* is positively associated with increased expression of SMOX in Colombian patients with *H. pylori*-associated gastritis, regardless of the region of residence. Therefore, methylation of *mir-124* potentially serves as a critical factor in determining general susceptibility to *H. pylori*-associated oxidative damage in the etiology of gastric cancer.

DISCUSSION

Chronic inflammation associated with *H. pylori* infection is perceived to have a causative role in epigenetic gene silencing through DNA hypermethylation, which increases as an individual progresses through the cascade from non-atrophic gastritis to cancer.^{31–33} As shown here with *mir-124*, methylation levels of other tumor suppressor genes involved in gastric carcinogenesis are also increased in the high-risk Colombian gastritis patients,^{34,35} suggesting a fundamental difference affecting the methylation process. Genetic differences, including ancestral variation in both the human and bacterial populations, also contribute to cancer risk.³⁶ Our group recently isolated and characterized multiple *H. pylori* strains from individuals inhabiting the high- or low-risk regions; interestingly, compared with those obtained from low-risk individuals, the strains from high-risk patients were capable of inducing significantly higher levels of SMOX activity and DNA damage with reduced apoptosis levels that were associated with activation of epidermal growth factor receptor.^{9,13} Therefore, in the high-risk region patients already predisposed to SMOX expression due to hypermethylated *mir-124* genes, there is also an increased chance of becoming colonized by an *H. pylori* strain with heightened ability to induce SMOX without triggering apoptosis.

The current study did not investigate the effects of miR-124 expression on cell proliferation and tumorigenic potential, as these have been previously reported in AGS cells among others. As would be expected for a miRNA with tumor-suppressive function, overexpressing miR-124 decreased proliferation rates and anchorage-independent growth in all tumor cell types examined, and mouse tumor xenografts originating from miR-124-overexpressing gastric carcinoma cells, including the AGS cell line used in the current study, resulted in significantly slower tumor growth.³⁷ As miR-124 has multiple potentially oncogenic targets, including regulators of proliferation such as CDK6,²⁴ it should be noted that in cells with silenced miR-124, growth is significantly upregulated concomitant with SMOX-mediated DNA damage and decreased apoptosis, again exacerbating the potential for malignancy.

Through identifying SMOX as a novel target of miR-124, the results of the current study suggest the aberrant epigenetic silencing of miR-124 as a potential risk indicator for *H. pylori*-associated gastric carcinogenesis. As exemplified in Figure 3 and schematically illustrated in Figure 7, when expressed in gastric epithelial cells, miR-124 targets and prevents the induction of SMOX-generated ROS that occurs in the presence of inflammatory stimuli, such as *H. pylori*-associated gastritis. As a result, gastritis patients expressing higher levels of miR-124 maintain lower levels of SMOX and appear less likely to progress through the higher-grade, premalignant lesions that lead to gastric cancer. In contrast, patients at high risk for progressing to gastric cancer demonstrate significantly higher levels of SMOX and oxidative DNA damage




Figure 6. Methylation levels of *mir-124* genes correlate with SMOX expression in gastritis patients at various stages of disease. In (a–c), generalized linear models were used to analyze the relationships between *mir-124* promoter methylation and SMOX expression in the human gastric biopsies from both high- and low-risk regions combined. Regression plots present SMOX immunohistochemistry staining scores versus the percent methylation of *mir-124-1*, *-2* or *-3* (black dots: low-risk region patients; red dots: high-risk region patients; patients within the top and bottom 10th percentiles of *mir-124* methylation were excluded from the plots but included in the multivariate analyses and calculations of *P*-values). In (d), the mean SMOX staining scores at the 10 and 90th percentiles of *mir-124* methylation (at each locus) are presented, with error bars indicating 95% confidence intervals.

that is associated with increased levels of *mir-124* CpG-island hypermethylation.

Our studies therefore suggest the potential use of methylated *mir-124* as a valuable indicator of gastric cancer risk in *H. pylori*-positive individuals. As greater than half of the world's population is infected with *H. pylori*, global antibiotic eradication of the bacteria is not feasible.³⁸ In addition to cost prohibitions, antibiotic resistance is a factor, and eradication only reduces the risk of gastric cancer if conducted before the occurrence of premalignant lesions.³⁹ As a biomarker, methylation of *mir-124* could provide an indicator for those patients most likely to progress to the premalignant lesions and cancer, who could then receive more intensive monitoring with appropriate eradication and/or chemopreventive strategies. In fact, without regard to its downstream effects, methylation of *mir-124-3* has shown utility as an accurate indicator of metachronous gastric cancers, in a multicenter cohort study.⁴⁰

Owing to the limitations of eradication, strategies for the chemoprevention of *H. pylori*-associated gastric carcinogenesis are needed to significantly reduce the risk associated with this pathogen. Preclinical data using a Mongolian gerbil model of *H. pylori*-associated gastric cancer has provided promising results with α -difluoromethylornithine, an inhibitor of polyamine biosynthesis, or MDL72 527, an inhibitor of SMOX.¹³ Both agents inhibited SMOX-mediated DNA damage and reduced the gastric dysplasia and carcinoma associated with *H. pylori* infection. A clinical trial using α -difluoromethylornithine, which reduces the abundance of spermine available for oxidation in the preclinical

gerbil model,¹³ is being initiated in Colombia. In this regard, the detection of *mir-124* hypermethylation could provide a feasible method for identifying the patients most likely to benefit from a therapy targeting the polyamine pathway. Additionally, although not specifically targeting SMOX, the fact that the mode of *mir-124* silencing is epigenetic indicates its reversibility and suggests the use of DNA methyltransferase inhibitors, such as 5-azacytidine, which have been extensively studied in the clinic and are currently being revisited for their lasting demethylating effects using transient dosing schedules at less cytotoxic concentrations.⁴¹ Finally, the utility of miRNAs themselves as potential anticancer drugs is an area of active investigation currently limited by a lack of efficient delivery systems.⁴²

Hypermethylation of *mir-124* has been observed in many other cancer types as well as in several premalignant conditions associated with chronic inflammation and/or infection. In particular, *mir-124* methylation increases in ulcerative colitis and has been identified as a potential risk marker for colitis-associated cancer,²² a condition that, like gastritis, varies greatly among individuals. As we have previously reported that elevated SMOX activity in an ETBF-induced model of mouse colitis is a mechanism linking inflammatory stimuli with tumorigenesis,⁷ we can speculate that miR-124 expression influences SMOX activity in this system as well. Moreover, the lack of miR-124 expression in multiple systems further implicates a fundamental role for SMOX induction in the etiology of chronic inflammation/infection-associated carcinogenesis that warrants further investigation.




Figure 7. The proposed mechanism of miR-124-mediated protection from *H. pylori*-induced tumorigenesis. **(a)** In *H. pylori*-positive gastritis patients with low levels of DNA methylation at the *mir-124* gene promoters, sufficient transcription occurs to enable post-transcriptional silencing of *SMOX* mRNA by mature miR-124. The result is a low level of SMOX protein induction in spite of transcriptional activation by *H. pylori*-associated inflammatory stimuli. **(b)** In *H. pylori*-positive patients with increased CpG-island methylation (Me) in the *mir-124* promoters, the abundance of mature miR-124 is reduced, and SMOX protein production is uncontrolled. The result is reduced concentrations of free-radical scavenging spermine combined with persistent ROS production, thereby increasing the likelihood of oxidative DNA damage known to contribute to the genetic and epigenetic changes associated with cancer. MRE, microRNA recognition element.

It should also be noted that infection/inflammation-associated, ROS-induced DNA damage has been directly implicated in the epigenetic silencing of tumor suppressor genes.⁴³ Consequently, the intriguing possibility exists that *mir-124* methylation and SMOX expression/activity may constitute a feedforward mechanism where increased SMOX expression resulting from *mir-124* methylation leads to more ROS production, increased *mir-124* methylation and thus more SMOX expression, as the lesions progress towards malignancy.

In conclusion, the current study links the aberrant DNA methylation of *mir-124* with the activation of spermine oxidation and consequential generation of oxidative DNA damage in the etiology of *H. pylori*-associated gastric cancer. Methylation levels of the *mir-124* genes are elevated in patients at heightened risk of progression to *H. pylori*-associated gastric adenocarcinoma, whereas low methylation levels in the low-risk population are associated with miR-124-mediated protection from SMOX induction. Therefore, the methylation or expression level of miR-124 may provide a useful marker for identifying those *H. pylori*-positive individuals at increased risk for developing gastric cancer.

MATERIALS AND METHODS

Cell lines, culture conditions and chemicals

The AGS human gastric cancer cell line, obtained from and authenticated by ATCC (CRL-1739; Manassas, VA, USA), was maintained in F12K medium containing 10% fetal bovine serum at 37 °C with 5% CO₂. Mycoplasma testing was performed using the MycoAlert Detection Kit (Lonza, Walkersville, MD, USA). All custom primers were synthesized by Integrated DNA Technologies (Coralville, IA, USA). Restriction and DNA modification enzymes were purchased from New England Biolabs (Billerica, MA, USA). Treatments with the DNA methyltransferase inhibitor 5-azaC (Sigma, St Louis, MO, USA) were conducted at the doses indicated and included a

change of medium with freshly diluted inhibitor every 48 h for a total of three treatments, followed by a 3-day rest.

RNA extraction, gene expression and miRNA expression studies

RNAiMAX (Life Technologies, Grand Island, NY, USA) was used to transfect AGS cells (2.5×10^5 cells per well in 6-well plates) with *mirVana* miRNA mimics (Life Technologies) corresponding to hsa-miR-124-3p or a negative control. After 24 h, total RNA was extracted using TRIzol reagent (Life Technologies) and quantified by spectrophotometry; cDNA was synthesized using qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD, USA). SYBR green-mediated, real-time PCR was performed using the primer pairs and annealing temperatures in Supplementary Table 1 with SYBR green SuperMix for iQ (Quanta Biosciences). The optimum annealing temperature for each primer pair was determined using temperature gradients followed by melt-curve analyses and visualization on 2% agarose gels with GelStar staining (Lonza) and KODAK Digital Science Image Analysis Software (Eastman Kodak Company, Rochester, NY, USA). Amplification was performed on a Bio-Rad MyiQ2 real-time PCR detection system with data collection by the iQ5 Optical System Software (Bio-Rad Laboratories, Hercules, CA, USA). In each quantitative PCR experiment, samples were analyzed in triplicate, normalized to the *GAPDH* reference gene and the fold-change in expression was determined relative to cDNA from untreated cells using the $2^{-\Delta\Delta C_t}$ algorithm.

For miRNA expression analysis, 1 µg of TRIzol-extracted RNA was converted to cDNA using the miScript II PCR System (SABiosciences, Frederick, MD, USA). SYBR-green-mediated quantitative PCR was performed using a miR-124-specific sense primer²⁴ with a universal antisense primer (SABiosciences), according to the manufacturer's recommendations. U6 snRNA was amplified as the normalization control. Amplification products were electrophoresed on 2% agarose gels, stained with GelStar, and visualized and photographed using the KODAK Digital Science Image Analysis software.

Analyses of SMOX protein and activity and intracellular polyamine pools

AGS cells were transfected with the hsa-miR-124-3p or negative control miRNA mimic for 24 or 48 h, collected and quick-frozen for analysis. SMOX activity was measured using a luminol-based assay measuring the production of hydrogen peroxide, as described previously.⁴⁴ Polyamine concentrations were determined as described previously.⁴⁵ Both assays were normalized relative to milligrams of total cellular protein determined using the method of Bradford.⁴⁶

For western blots, total protein (50 µg per lane) was separated on precast 4–12% Bis-Tris NuPAGE gels with 1×MOPS running buffer (Invitrogen) and transferred onto Immun-Blot PVDF membranes (Bio-Rad). Blots were blocked for 1 h at room temperature in Odyssey blocking buffer (LI-COR, Lincoln, NE, USA), followed by overnight incubation at 4°C with antibodies specific to SMOX (1:1000 dilution), as described previously,² and β-actin (no. sc-8432; Santa Cruz Biotechnology, Dallas, TX, USA). Incubation with species-specific, fluorophore-conjugated secondary antibodies allowed the visualization and quantification of immunoreactive proteins using the Odyssey Infrared Detection System and Software (LI-COR).

Analysis of the 3′-UTR of SMOX

Putative hsa-miR-124 binding sites in the 3′-UTR of the human *SMOX* transcript were predicted using bioinformatic tools available at www.microrna.org⁴⁷ and TargetScan (version 6.2).⁴⁸ To experimentally verify that miR-124 could directly influence *SMOX* mRNA expression, an 86-bp region of the human *SMOX* 3′-UTR (+227 to +313) including the putative recognition element for miR-124 was PCR-amplified and inserted downstream of the luciferase gene in the pMIR-REPORT Luciferase expression vector (Life Technologies). Site-directed mutagenesis of the miR-124 seed recognition sequence in the *SMOX* 3′-UTR was accomplished using the QuikChange II system (Agilent Technologies, Santa Clara, CA, USA), and resulting plasmids were verified by sequencing. Co-transfection of the pMIR-Luc-*SMOX* plasmid (wild-type or mutant), the *mirVana* hsa-miR-124-3p mimic or negative control mimic, and the pMIR-REPORT-β-Gal reporter control plasmid into AGS cells was performed using Lipofectamine 2000 (Life Technologies). Cell lysates were collected 48 h later in reporter lysis buffer, and luciferase and β-galactosidase activities were measured using Luciferase and β-Galactosidase Enzyme Assay Systems, respectively (Promega, Madison, WI, USA). Luciferase activity was measured as relative light units and normalized to β-gal activity measurements determined by absorbance at OD₄₂₀. Additionally, a stable AGS cell line was created by transfection with a plasmid containing the *SMOX* coding region and the first 158 nucleotides of the 3′-UTR (lacking the miR-124 target site). Following transfection with the miR-124 or -NC mimic, quantitative real-time PCR (qRT-PCR) for *SMOX* was conducted as described above.

H. pylori culture and infection of AGS cells

H. pylori strain 60190 (ATCC) was maintained on trypticase soy agar plates containing 5% sheep blood at 37°C with 5% CO₂. In preparation for the infection of AGS cells, the bacteria were transferred to 75-cm² tissue culture flasks containing Brucella broth supplemented with 10% fetal bovine serum and grown for 48 h in an upright position with occasional agitation at 37°C with 5% CO₂. Bacteria were then collected by centrifugation, washed with phosphate-buffered saline, and cell number was estimated based on OD₆₀₀.

AGS gastric epithelial cells transfected with the miR-NC or miR-124-3p mimic were divided and replated in antibiotic-free F12K medium supplemented with 10% fetal bovine serum for 24 h before the addition of *H. pylori* at a multiplicity of infection of 100 for 6 h. Uninfected cells from the same transfected population were used as negative controls. Cells were harvested and lysates prepared for RNA extraction or SMOX activity and protein analysis.

Human subjects

The human gastric biopsies used in the current study were obtained previously following the provision of informed consent and according to Institutional Review Board protocols approved by Vanderbilt University and Universidad del Valle Ethics Committees.^{13,34,35} Briefly, samples were obtained by upper endoscopy from 90 patients with dyspeptic symptoms who resided in either the high-risk Andean Mountain community of Tuquerres (47 patients) or the low-risk Pacific Coast city of Tumaco (43 patients), both in the Department of Nariño, Colombia. *H. pylori* infection status, *cagA* genotype and SMOX

expression values were scored by a pathologist (MBP) blinded to the patient groups, as described previously.^{13,35,49}

Quantitative DNA methylation analyses

DNA was isolated from the frozen human gastric antral biopsies and used for bisulfite modification, PCR amplification and pyrosequencing as described previously.³⁵ Multiple primer pairs were designed specifically for each of the three gene loci of *hsa-mir-124* as follows: *mir-124-1* forward (mir124a-1PF) 5′-GGAGTTTTTTAGAAGTAGGTTTGATGTT-3′ and reverse (mir124a-1PR) 5′-biotin-CTCCCCCTCCCTAAACCCTCCAAC-3′;⁵⁰ *mir-124-2* forward (mir124a-2G) 5′-AGGAGGGAATTATTGTTTTTAGATAGTTG-3′ and reverse (mir124a-2H) 5′-biotin-AAAAAACTCCTACTTTCCATTACAAC-3′; and *mir-124-3* forward (mir124a-3F) 5′-AAGAGAGAGATTTTTTTTATGAGTAT-3′ and reverse (mir124a-3R) 5′-biotin-TCCTCCTCACTACCTTCCCCTA-3′.⁵⁰ The production of a single product for each primer pair was verified by electrophoresis in a 2% agarose gel. Methylated HeLa cell DNA (New England Biolabs) and normal human blood DNA were included in each experiment as positive and negative controls, respectively. Sequencing primers for each amplification product were as follows: *mir-124-1* (mir124a-1PS) 5′-TAGAAGTAGGTTTGATGT-3′; *mir-124-2* (mir124a-2GS) 5′-AATTTTTT AGGAGATT-3′; and *mir-124-3* (mir124a-3FS) 5′-GAGATTATTTTTTAAT-3′. Methylation was quantitated across the following regions of hg19: *mir-124-1*, chr8 (9 764 472–9 764 488); *mir-124-2*, chr8 (65 291 958–65 291 986); and *mir-124-3*, chr20 (61 809 423–61 809 438).

Statistical analyses

Data from *in vitro* experiments were analyzed using Student's *t*-test and Spearman's rank correlations, where appropriate. For patient data, correlation coefficients and their corresponding *P*-values were used to characterize bivariate relationships for variables normally distributed (Pearson's) or not (Spearman's). Generalized linear models with a Gaussian link were used to estimate the association between SMOX expression and *mir-124* methylation after adjusting for confounding variables that included age, *H. pylori* status, *cagA* status and histopathology score. Multivariate analyses were conducted using STATA 14 (StataCorp LP, College Station, TX, USA).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank Alberto Delgado for his technical expertise and performance of SMOX immunohistochemistry studies. This study was supported by National Institutes of Health Grants R01CA051085 and R01CA098454 (to RAC), R01DK053620 and R01CA190612 (to KTW), P01CA028842 (to PC and KTW), P01CA116087 (to KTW), K01AT007324 (to RC), the Samuel Waxman Cancer Research Foundation (to RAC), the Vanderbilt Digestive Disease Research Center grant (P30DK058404), UL1RR024975 (Vanderbilt CTSA, Pilot Project to KTW) and Merit Review Grant 1101BX001453 from the Office of Medical Research, Department of Veterans Affairs (to KTW).

AUTHOR CONTRIBUTIONS

TMS, KTW and RAC designed the research; TMS, JCS, MBP, RC and BGS performed the research; LEB and PC provided unique human samples; TMS, MBP, RMM, KTW and RAC analyzed the data; and TMS, KTW and RAC wrote the paper. All authors revised and approved the final manuscript.

REFERENCES

- Wang Y, Devereux W, Woster PM, Stewart TM, Hacker A, Casero RA Jr. Cloning and characterization of a human polyamine oxidase that is inducible by polyamine analogue exposure. *Cancer Res* 2001; **61**: 5370–5373.
- Murray-Stewart T, Wang Y, Goodwin A, Hacker A, Meeker A, Casero RA Jr. Nuclear localization of human spermine oxidase isoforms—possible implications in drug response and disease etiology. *FEBS J* 2008; **275**: 2795–2806.
- Cervelli M, Bellini A, Bianchi M, Marocchi L, Nocera S, Polticelli F *et al*. Mouse spermine oxidase gene splice variants. Nuclear subcellular localization of a novel active isoform. *Eur J Biochem* 2004; **271**: 760–770.
- Ha HC, Sirisoma NS, Kuppusamy P, Zweier JL, Woster PM, Casero RA Jr. The natural polyamine spermine functions directly as a free radical scavenger. *Proc Natl Acad Sci USA* 1998; **95**: 11140–11145.

- 5 Chaturvedi R, Cheng Y, Asim M, Bussiere FI, Xu H, Gobert AP *et al*. Induction of polyamine oxidase 1 by *Helicobacter pylori* causes macrophage apoptosis by hydrogen peroxide release and mitochondrial membrane depolarization. *J Biol Chem* 2004; **279**: 40161–40173.
- 6 Xu H, Chaturvedi R, Cheng Y, Bussiere FI, Asim M, Yao MD *et al*. Spermine oxidation induced by *Helicobacter pylori* results in apoptosis and DNA damage: implications for gastric carcinogenesis. *Cancer Res* 2004; **64**: 8521–8525.
- 7 Goodwin AC, Destefano Shields CE, Wu S, Huso DL, Wu X, Murray-Stewart TR *et al*. Polyamine catabolism contributes to enterotoxigenic *Bacteroides fragilis*-induced colon tumorigenesis. *Proc Natl Acad Sci USA* 2011; **108**: 15354–15359.
- 8 Babbar N, Casero RA Jr. Tumor necrosis factor- α increases reactive oxygen species by inducing spermine oxidase in human lung epithelial cells: a potential mechanism for inflammation-induced carcinogenesis. *Cancer Res* 2006; **66**: 11125–11130.
- 9 Chaturvedi R, Asim M, Piazzuelo MB, Yan F, Barry DP, Sierra JC *et al*. Activation of EGFR and ERBB2 by *Helicobacter pylori* results in survival of gastric epithelial cells with DNA damage. *Gastroenterology* 2014; **146**: 1739–1751, 1714.
- 10 Goodwin AC, Jadallah S, Toubaji A, Lecksell K, Hicks JL, Kowalski J *et al*. Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues. *Prostate* 2008; **68**: 766–772.
- 11 Hong SK, Chaturvedi R, Piazzuelo MB, Coburn LA, Williams CS, Delgado AG *et al*. Increased expression and cellular localization of spermine oxidase in ulcerative colitis and relationship to disease activity. *Inflamm Bowel Dis* 2010; **16**: 1557–1566.
- 12 Chaturvedi R, Asim M, Romero-Gallo J, Barry DP, Hoge S, de Sablet T *et al*. Spermine oxidase mediates the gastric cancer risk associated with *Helicobacter pylori* CagA. *Gastroenterology* 2011; **141**: 1696–1708, 1691 and 1692.
- 13 Chaturvedi R, de Sablet T, Asim M, Piazzuelo MB, Barry DP, Verriere TG *et al*. Increased *Helicobacter pylori*-associated gastric cancer risk in the Andean region of Colombia is mediated by spermine oxidase. *Oncogene* 2015; **34**: 3429–3440.
- 14 Goodwin CS. *Helicobacter pylori* gastritis, peptic ulcer, and gastric cancer: clinical and molecular aspects. *Clin Infect Dis* 1997; **25**: 1017–1019.
- 15 Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to *Helicobacter pylori*. *Int J Cancer* 2015; **136**: 487–490.
- 16 Peek RM Jr, Blaser MJ. *Helicobacter pylori* and gastrointestinal tract adenocarcinomas. *Nat Rev Cancer* 2002; **2**: 28–37.
- 17 Malfertheiner P, Sipponen P, Naumann M, Moayyedi P, Megraud F, Xiao SD *et al*. *Helicobacter pylori* eradication has the potential to prevent gastric cancer: a state-of-the-art critique. *Am J Gastroenterol* 2005; **100**: 2100–2115.
- 18 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015; **65**: 87–108.
- 19 Camargo MC, Yeppez MC, Ceron C, Guerrero N, Bravo LE, Correa P *et al*. Age at acquisition of *Helicobacter pylori* infection: comparison of two areas with contrasting risk of gastric cancer. *Helicobacter* 2004; **9**: 262–270.
- 20 Correa P, Cuello C, Duque E, Burbano LC, Garcia FT, Bolanos O *et al*. Gastric cancer in Colombia. III. Natural history of precursor lesions. *J Natl Cancer Inst* 1976; **57**: 1027–1035.
- 21 Ando T, Yoshida T, Enomoto S, Asada K, Tatematsu M, Ichinose M *et al*. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. *Int J Cancer* 2009; **124**: 2367–2374.
- 22 Ueda Y, Ando T, Nanjo S, Ushijima T, Sugiyama T. DNA methylation of microRNA-124a is a potential risk marker of colitis-associated cancer in patients with ulcerative colitis. *Dig Dis Sci* 2014; **59**: 2444–2451.
- 23 Shi XB, Xue L, Ma AH, Tepper CG, Gaudin-Edwards R, Kung HJ *et al*. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. *Oncogene* 2013; **32**: 4130–4138.
- 24 Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F *et al*. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. *Cancer Res* 2007; **67**: 1424–1429.
- 25 Ushijima T, Hattori N. Molecular pathways: involvement of *Helicobacter pylori*-triggered inflammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers. *Clin Cancer Res* 2012; **18**: 923–929.
- 26 Koukos G, Polyarchou C, Kaplan JL, Morley-Fletcher A, Gras-Mirallas B, Kokkoto E *et al*. MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. *Gastroenterology* 2013; **145**: 842–852, 842.
- 27 Wilting SM, van Boerdonk RA, Henken FE, Meijer CJ, Diosdado B, Meijer GA *et al*. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. *Mol Cancer* 2010; **9**: 167–181.
- 28 Rider JE, Hacker A, Mackintosh CA, Pegg AE, Woster PM, Casero RA Jr. Spermine and spermidine mediate protection against oxidative damage caused by hydrogen peroxide. *Amino Acids* 2007; **33**: 231–240.
- 29 Pegg AE, Xiong H, Feith DJ, Shantz LM. S-adenosylmethionine decarboxylase: structure, function and regulation by polyamines. *Biochem Soc Trans* 1998; **26**: 580–586.
- 30 Hardbower DM, de Sablet T, Chaturvedi R, Wilson KT. Chronic inflammation and oxidative stress: the smoking gun for *Helicobacter pylori*-induced gastric cancer? *Gut Microbes* 2013; **4**: 475–481.
- 31 Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M *et al*. High levels of aberrant DNA methylation in *Helicobacter pylori*-infected gastric mucosae and its possible association with gastric cancer risk. *Clin Cancer Res* 2006; **12**: 989–995.
- 32 Nakajima T, Maekita T, Oda I, Gotoda T, Yamamoto S, Umemura S *et al*. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. *Cancer Epidemiol Biomarkers Prev* 2006; **15**: 2317–2321.
- 33 Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T *et al*. Inflammatory processes triggered by *Helicobacter pylori* infection cause aberrant DNA methylation in gastric epithelial cells. *Cancer Res* 2010; **70**: 1430–1440.
- 34 Schneider BG, Piazzuelo MB, Sicinski LA, Mera R, Peng DF, Roa JC *et al*. Virulence of infecting *Helicobacter pylori* strains and intensity of mononuclear cell infiltration are associated with levels of DNA hypermethylation in gastric mucosae. *Epigenetics* 2013; **8**: 1153–1161.
- 35 Schneider BG, Peng DF, Camargo MC, Piazzuelo MB, Sicinski LA, Mera R *et al*. Promoter DNA hypermethylation in gastric biopsies from subjects at high and low risk for gastric cancer. *Int J Cancer* 2010; **127**: 2588–2597.
- 36 Kodaman N, Pazos A, Schneider BG, Piazzuelo MB, Mera R, Sobota RS *et al*. Human and *Helicobacter pylori* coevolution shapes the risk of gastric disease. *Proc Natl Acad Sci USA* 2014; **111**: 1455–1460.
- 37 Xie L, Zhang Z, Tan Z, He R, Zeng X, Xie Y *et al*. MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer. *Mol Cell Biochem* 2014; **392**: 153–159.
- 38 Dalal RS, Moss SF. At the bedside: *Helicobacter pylori*, dysregulated host responses, DNA damage, and gastric cancer. *J Leukoc Biol* 2014; **96**: 213–224.
- 39 Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. *Helicobacter pylori* eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. *BMJ* 2014; **348**: 3174–3187.
- 40 Asada K, Nakajima T, Shimazu T, Yamamichi N, Maekita T, Yokoi C *et al*. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. *Gut* 2015; **64**: 388–396.
- 41 Tsai H-C, Li H, Van Neste L, Cai Y, Robert C, Rassool FV *et al*. Transient low doses of DNA demethylating agents exert durable anti-tumor effects on hematological and epithelial tumor cells. *Cancer Cell* 2012; **21**: 430–446.
- 42 Wang H, Jiang Y, Peng H, Chen Y, Zhu P, Huang Y. Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors. *Adv Drug Deliv Rev* 2015; **81**: 142–160.
- 43 O'Hagan HM, Wang W, Sen S, Destefano Shields C, Lee SS, Zhang YW *et al*. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG islands. *Cancer Cell* 2011; **20**: 606–619.
- 44 Wang Y, Murray-Stewart T, Devereux W, Hacker A, Frydman B, Woster PM *et al*. Properties of purified recombinant human polyamine oxidase, PAOh1/SMO. *Biochem Biophys Res Commun* 2003; **304**: 605–611.
- 45 Kabra PM, Lee HK, Lubich WP, Marton LJ. Solid-phase extraction and determination of dansyl derivatives of unconjugated and acetylated polyamines by reversed-phase liquid chromatography: improved separation systems for polyamines in cerebrospinal fluid, urine and tissue. *J Chromatogr* 1986; **380**: 19–32.
- 46 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976; **72**: 248–254.
- 47 Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. *Nucleic Acids Res* 2008; **36**: D149–D153.
- 48 Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 2005; **120**: 15–20.
- 49 de Sablet T, Piazzuelo MB, Shaffer CL, Schneider BG, Asim M, Chaturvedi R *et al*. Phylogeographic origin of *Helicobacter pylori* is a determinant of gastric cancer risk. *Gut* 2011; **60**: 1189–1195.
- 50 Shimizu T, Suzuki H, Nojima M, Kitamura H, Yamamoto E, Maruyama R *et al*. Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer. *Eur Urol* 2013; **63**: 1091–1100.

Supplementary Information accompanies this paper on the Oncogene website (<http://www.nature.com/onc>)